Purpose: This case report reveals the effect of the diode laser photocoagulation in Central Serous Chorioretinopathy.
Case Report: A 49 years old male has been referred to us for a decrease in the central vision (2/10) for 4 months. The clinical examination of the retina and the angiophluorography have diagnosed a classical form of Central Serous Chorioretinopathy, with a unique leaking point, situated away from the fovea. The focal diode laser photocoagulation of the leaking point has been performed and 6 weeks after treatment, the visual acuity has normalized (10/10) and the angiophluorography has proven no sign of activity.
Discussion: The etiopathogenetic, clinical and evolutive aspects of this case are discussed in comparison to the data in the literature.
Conclusion: The focal diode laser photocoagulation of the leaking point has led to immediate anatomical and functional success in Central Serous Chorioretinopathy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Reply to letter to editor: (Is Pachychoroid Serous Retinopathy a Better Name to Describe the Features of Central Serous Chorioretinopathy?).
Retina
December 2024
Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California Los Angeles, Los Angeles, CA, United State.
Intravitreal steroid-associated central serous chorioretinopathy.
BMJ Case Rep
January 2025
Ophthalmology, JIPMER, Puducherry, India.
Central serous chorioretinopathy (CSC) is a known side effect of systemic steroid therapy. The role of intravitreal steroids in causing CSC is controversial. We present two cases of acute CSC that developed after intravitreal steroid injections.
View Article and Find Full Text PDFChoroidal Response to Intravitreal Bevacizumab Injections in Treatment-Naïve Macular Neovascularization Secondary to Chronic Central Serous Chorioretinopathy.
Biomedicines
December 2024
Tel Aviv Medical Center, Department of Ophthalmology, Tel Aviv University, Tel Aviv 6423906, Israel.
Background/objectives: To evaluate the impact of intravitreal bevacizumab (IVB) therapy on anatomical and visual outcomes in patients with macular neovascularization (MNV) secondary to chronic central serous chorioretinopathy (cCSC).
Methods: This retrospective observational study reviewed the medical records of treatment-naïve patients diagnosed with cCSC complicated by MNV and treated with IVB injections over a 5-year period. The presence of MNV was confirmed using optical coherence tomography angiography (OCTA).
Objective: To investigate the long-term impact of half-fluence photodynamic therapy (PDT) on chorioretinal architecture in chronic central serous chorioretinopathy (cCSCR) through novel choroidal vascularity index (CVI) versus previously established subfoveal choroidal thickness (SFCT).
Methods: This post-hoc analysis included prospectively collected swept-source optical coherence tomography (SS-OCT) images of a total of 29 cCSCR and fellow eyes (FE), acquired before, one and 12 months after PDT. CVI, total choroidal area (TCA), luminal area (LA) and stromal area (SA) were calculated using validated binarization technique.
Outcomes and predictive factors for fluid resolution following three loading injections of faricimab for treatment-naïve neovascular age-related macular degeneration.
Sci Rep
January 2025
Department of Ophthalmology, Kim's Eye Hospital, #156 Youngdeungpo-dong 4ga, Youngdeungpo-gu, 150-034, Seoul, South Korea.
To evaluate the outcomes and predictive factors for fluid resolution following three loading injections of faricimab for neovascular age-related macular degeneration(AMD). This retrospective study included patients diagnosed with treatment-naïve neovascular AMD who received three monthly injections of faricimab. Changes in best-corrected visual acuity(BCVA) and central retinal thickness(CRT) following treatment were evaluated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!